Corient Private Wealth LLC Has $7.25 Million Holdings in Omeros Co. (NASDAQ:OMER)

Corient Private Wealth LLC trimmed its holdings in Omeros Co. (NASDAQ:OMER) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 733,449 shares of the biopharmaceutical company’s stock after selling 53,002 shares during the period. Corient Private Wealth LLC owned 1.27% of Omeros worth $7,246,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in OMER. Truvestments Capital LLC raised its holdings in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares during the period. MML Investors Services LLC lifted its holdings in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the last quarter. State Street Corp boosted its stake in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares during the period. HighTower Advisors LLC grew its holdings in Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 4,000 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Omeros by 21.2% during the 4th quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 4,257 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on OMER. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 1.3 %

Shares of Omeros stock opened at $9.10 on Friday. The stock has a market cap of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03. Omeros Co. has a twelve month low of $2.61 and a twelve month high of $13.60. The company’s fifty day moving average is $8.70 and its 200 day moving average is $7.28.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.